Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemborexant in ISWRD and Alzheimer's Disease
NCT03001557Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of lemborexant in Irregular sleep-wake rhythm disorder (ISWRD) (5 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Actigraphy Sleep Efficiency at 4 weeks, Sleep Fragmentation Index at 4 weeks and 10 more. Started Dec 2016; status: completed.
02
Drugs
lemborexant
03
Conditions
Irregular sleep-wake rhythm disorder (ISWRD)
Beyond the preview
Go deeper on NCT03001557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03001557.